5:30 PM
Aug 18, 2014
 |  BC Extra  |  Clinical News

NCI launches second precision medicine master protocol

The National Clinical Trials Network (NCTN) launched the ALCHEMIST protocol to identify early stage non-small cell lung cancer (NSCLC) patients with tumors that harbor genetic mutations to understand how early intervention can improve survival outcomes for patients who have undergone complete surgical resection of tumors.

Response Genetics Inc. (NASDAQ:RGDX) will screen surgically removed tissue from 8,000 patients to identify...

Read the full 283 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >